Problem {#s1}
=======

This article describes a quality improvement (QI) project improving care for patients undergoing elective oesophagogastric surgery; our unit performs approximately 120 oesophagogastric resections each year. The project has been conducted over 4 years in a large teaching hospital managing a mixed patient cohort within a busy preoperative assessment clinic (PAC) (\>12 000 patients/annum). The project was led by the preoperative assessment team, with the support of members of the wider multidisciplinary team at the Royal Victoria Infirmary, Newcastle upon Tyne; ward staff and specialist nurses managing this group of patients have been integral to the success of this initiative.

In 2014, a gap analysis of the many facets of patient blood management (PBM[@R1]) was conducted within preoperative assessment and surgical pathways as part of a larger trust-wide gap analysis to assess our compliance with PBM, coordinated by our transfusion committee. This collection of audits was led by the author (RS) and addressed blood transfusion, transfusion triggers, cell salvage, blood conservation techniques, use of tranexamic acid and all other facets of PBM pertaining to the surgical pathway. The most notable area for improvement highlighted from this work was preoperative anaemia: it was demonstrated from data collection that there was a high incidence of anaemia in patients attending for gastrointestinal surgery (upper gastrointestinal and colorectal surgery), which was not being actively managed preoperatively. This patient group is known to have a high incidence of iron deficiency anaemia.[@R2]

The primary objective was therefore to treat preoperative iron deficiency anaemia before major surgery, focusing on patients undergoing gastro-oesophageal surgery, in line with the principles promoted by the PBM initiative.[@R1] The secondary objective was to reduce the number of blood transfusions for this group of patients, as a consequence of treating iron deficiency.

Background {#s2}
==========

Optimising preoperative Hb, including the treatment of iron deficiency anaemia, is recommended before elective surgery.[@R3] Recently, this has been driven by the publication of National Institute for Clinical Excellence (NICE) Quality Standards for Transfusion,[@R7] which state that patients with iron deficiency anaemia who are having surgery should be offered iron supplementation before and after surgery.[@R7] The NHS and Department of Health PBM initiative has served to promote a multidisciplinary, evidence-based approach to optimise best practice in detecting and managing preoperative anaemia.[@R1]

NICE states that iron supplementation can reduce the need for blood transfusion and avoid the serious risks that are associated with transfusion.[@R7] Further, NICE proposes that hospital length of stay and cost to the NHS may be reduced by this intervention.[@R7] Perioperative blood transfusion is associated with an increased risk of postoperative morbidity and mortality in some surgical patients.[@R9]

The incidence of anaemia is high in the elective surgical population, between 30% and 40%, depending on diagnostic criteria and the population studied.[@R9] Anaemia is independently associated with an increased risk of 30-day mortality and morbidity in patients having major non-cardiac surgery.[@R9] This effect is demonstrated in both mild--moderate and severe anaemia. Furthermore, the addition of a second risk factor (respiratory, cardiac disease, diabetes and sepsis) in combination with anaemia further increases the adjusted OR for 30-day morbidity and mortality.[@R9] Preoperative anaemia is also associated with increased postoperative blood transfusion[@R11]; however, as surgery has evolved, the requirements for transfusion have decreased in many specialities, resulting in fewer transfusions. Nonetheless, a higher starting preoperative Hb may avoid the requirement for postoperative blood transfusion in patients who might otherwise have undergone this were they were anaemic preoperatively.[@R14]

The consensus guidance document published by Muñoz *et al* in 2017 outlines a summary guideline for improved clinical practice in this area.[@R15] This expert group recommends a pathway of anaemia management that begins before surgery and manages the patient through to successful recovery and discharge. The group recommends that this should be considered for all patients who are at risk of moderate to high blood loss, defined as \>500 mL.[@R15]

Measurement {#s3}
===========

Data for each stage of analysis during this project were collected from the same sources. The reproducible population to be studied was defined at the outset as those patients undergoing major oesophagogastric cancer resections whose management and outcomes are recorded on the local oesophagogastric cancer database. At each stage of analysis, the details for patients undergoing surgery during a 6-month period were extracted from the database. The results of blood investigations were retrieved from the local electronic record system and blood transfusion data sourced from the blood transfusion laboratory local database, which records all blood products administered within the trust. The data were thus reliable and valid.

Our project design was pragmatic, and while it is not possible to fully exclude confounding factors that may have influenced the rate of transfusion, there were no significant changes to other aspects of the patients' perioperative and surgical care during the intervention period.

The following definitions describe the measured data for each audit cycle:

-   Presenting Hb and ferritin: the Hb concentration and ferritin level measured at the first attendance at the PAC.

-   Preoperative Hb: the Hb concentration measured 24 hours before surgery, or where this was unavailable on the date closest to surgery within the preceding 7 days.

-   Discharge Hb: the last measured Hb before discharge of the patient from the hospital after the major surgery episode.
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-   Units of blood transfused: units of red cells transfused within the perioperative period and before discharge from the hospital during the major surgery episode (ie, intraoperative and postoperative transfusions).

Baseline data (2013--2014) {#s3-1}
--------------------------

The baseline preoperative Hb measured for the group had a median of 125.4 g/L (range 77--171 g/L).

During this baseline audit, anaemia was defined as Hb\<120 g/L for women and Hb\<130 g/L for men. This incidence of anaemia using these criteria was 40.9%. The incidence of anaemia, as subsequently defined by the Munoz et al consensus statement (Hb\<130 g/L for all patients), was 58% at baseline.

Severe preoperative anaemia (Hb\<100 g/L) was observed in 10% of patients.

Postoperatively, 33 units of blood were transfused to 14 patients (16% of patients): most of this blood was given more than 7 days after surgery.

As the project evolved, we were able to collect data additional to the baseline dataset, including presenting Hb and ferritin, and discharge Hb.

Design {#s4}
======

We designed an approach to identify and treat iron deficiency anaemia that was minimally disruptive to the care pathways of this group of patients. We were conscious that these patients attend a large number of hospital appointments while they have a 'work-up' of their cancer treatment plan. Rather than add to the burden of appointments, we realised that this presented several potential opportunities to treat patients (while they attended other appointments at the hospital). Thus, our intervention was delivered within the structure of the current care pathway. We used the multiple hospital appointments attended in their work-up as opportunities for delivery of treatment interventions.

Each patient presenting to the preoperative assessment service is assessed early within the cancer pathway (before final multidisciplinary team (MDT) decision making) and then has a second updated assessment in the 2 weeks before major surgery. The pathway is designed in this way to accommodate early diagnosis and management, which can contribute to MDT discussion, provide an opportunity to address modifiable risk factors and enable review following the physiological insult of neoadjuvant chemotherapy (70% of this patient group underwent neoadjuvant chemotherapy prior to surgery). In addition to the other investigations performed at this initial assessment, Hb and ferritin were measured and interpreted by the consultant anaesthetist in the PAC.

The decision to treat anaemia was based on locally agreed Hb and ferritin thresholds (see [figure 1](#F1){ref-type="fig"}). It will be noted that these differ from the threshold values recommended more recently[@R15]; this local pathway was novel and exploratory and predated consensus guidance.

![QI cycle 1 decision tool.](bmjoq-2019-000776f01){#F1}

In the early stages of the project, the intervention was managed by the consultant anaesthetist who reviewed each patient and the oesophagogastric specialist nursing staff. The specialist nurses coordinated the administration of intravenous iron for patients while they attended other appointments on the day case ward, after instructions from the anaesthetist. The key team members at this stage were two consultant anaesthetists and two specialist nurses.

Strategy {#s5}
========

Improvement cycle 1 (2015) {#s5-1}
--------------------------

Hb and ferritin were measured at the PAC and interpreted by a consultant anaesthetist. The decision to treat iron deficiency was based on locally agreed Hb and ferritin thresholds (see [figure 1](#F1){ref-type="fig"}); it will be noted that these differ from the threshold values recommended more recently.[@R15] The primary intervention in this first QI cycle was the prescription and administration of 1 g of intravenous ferric carboxymaltose to patients with Hb\<120 g/L (female) or \<130 g/L (male) and ferritin\<20 μg/L. This was administered on the hospital day case ward: commonly, the infusion was completed during an appointment when the patient was attending for other investigations. Appointments were organised by the specialist nurses and coordinated with other attendances.

Improvement cycle 2 (January 2018) {#s5-2}
----------------------------------

Analysis of Hb and blood transfusion data over the period of June--November 2017 was performed as described previously. This time period was chosen as it allowed enough time for the clinical team to have become familiar with, and thus consistently implement, the cycle 1 intervention. An improvement in preoperative Hb concentration and a decrease in the number of units of blood transfused were demonstrated (see [table 1](#T1){ref-type="table"}).

###### 

Characteristics of patients included in each timed data collection at baseline (2013--2014) and after PDSA cycle 1 (2017) and cycle 3 (2018)

                                           December 2013--June 2014     February--July 2017        June--November 2018
  ---------------------------------------- ---------------------------- -------------------------- --------------------------
  n                                        88                           62                         61
  Age (years)                              66 (33--83)                  67 (26--86)                72 (44--88)
  M:F                                      61:27                        40:21                      43:18
  Surgery                                                                                          
   STO                                     33                           34                         37
   STG                                     32                           13                         14
   TG                                      12                           11                         7
   Wedge resection                         2                            3                          0
   Other                                   4                            1                          2
  Length of stay, critical care (days\*)   1 (0--2) (0--14)             2 (0--3) (0--24)           2 (2.0--4.5) (0--240)
  Length of say in the hospital (days)     11.5 (9--16) (0--47)         9.5 (7--16) (3--167)       10 (8.0--15.5) (3--40)†
  In-hospital mortality                    1                            2                          0
  Presenting Hb at PAC (g/L)               --                           122 (122--146) (88--159)   132 (117--144) (77--179)
  Preoperative Hb (g/L)                    125.4 (116--136) (77--171)   131 (119--137) (98--159)   130 (120--140) (95--174)

Values are median (IQR) (range).

\*Critical care admission length of stay is calculated from the number of calendar days or part days that the patient was cared for in critical care.

†One patient remains an inpatient at the time of writing (240 days), awaiting home ventilator support for discharge.

Hb, haemoglobin; PAC, preoperative assessment clinic; PDSA, plan--do--study--act; STG, subtotal gastrectomy; STO, two-stage subtotal oesophagectomy; TG, total gastrectomy.

On the basis of this evidence of improvement, a second QI cycle was commenced.

Cycle 2 comprised the following composite bundle of improved interventions (see [figure 2](#F2){ref-type="fig"}).

![Interventions in cycle 2.](bmjoq-2019-000776f02){#F2}

First, we decided to change our intravenous iron product in order to facilitate a single optimal dose of intravenous iron to be given in a single day case attendance. We are a tertiary centre covering a large geographical area. The previous intervention consisted of a standardised capped dose of intravenous iron (ferric carboxymaltose 1 g). In order to give a higher dose of iron (to patients with very low Hb or high body weight), a second attendance for day case infusion would have been required: this was perceived as inconvenient to patients and also complicated our patient pathways. Thus, we changed our iron prescription to iron isomaltoside 1000, allowing a weight-based optimised dose of iron to be given in a single attendance.

Second, in conjunction with hospital pharmacists, we developed and introduced a trust-wide guideline on the treatment of iron deficiency anaemia in the perioperative setting. This guideline directs the identification, prescription and safe administration of intravenous iron to adult patients and also acts as the prescription and record of administration.

Following the publication of international consensus guidelines,[@R15] we changed the definition of anaemia to Hb\<130 for all patients, and the ferritin threshold was raised from \<20 to \<30.

A final change was to the arrangements for the administration of intravenous iron. Following discussion with the manager of the day case ward, it was agreed that the nursing team in PAC could liaise directly with the ward team to book appointments for infusions, removing this workload from the specialist nurses.

Improvement cycle 3 (September 2018) {#s5-3}
------------------------------------

The intervention in the third cycle was introduced before the full analysis of cycle 2 interventions. Increased consultant and nurse staffing within our preoperative assessment service allowed the introduction of a 'one-stop, same-day' anaemia treatment initiative for all patients undergoing major gastrointestinal surgery. While we recognised that we were making a further change without having fully studied the impact of the previous interventions, it was not felt that this would significantly affect our primary and secondary outcomes, but had the potential to immediately improve the patient experience.

Thus, in September 2018, we introduced point-of-care (POC) Hb testing to our PAC. This was done to facilitate the ability to diagnose and treat preoperative anaemia in high-risk patients at a single hospital attendance. When patients attending our high-risk clinics (including the oesophagogastric patient population) arrive in the clinic, they have a POC Hb measurement (Hemocue Hb 201, Angelholm, Sweden). If the POC measurement demonstrates an Hb of \<130 g/L, then the blood tests for that individual are taken immediately and sent as priority to the laboratory: this enables us to retrieve the results for these patients urgently and to make a decision about treatment based on Hb, ferritin and CRP.[@R15] Given that this patient group is predominantly undergoing treatment for malignant and inflammatory conditions, ferritin, as an acute phase protein, may be elevated; where the diagnosis of iron deficiency anaemia cannot be excluded by this first line set of tests, we have the opportunity to add appropriate further blood test orders if required. At this point, approximately 2 hours after the first POC Hemocue test, we can add iron studies (transferrin saturations±iron and total iron binding capacity) as clinically indicated to the laboratory order without repeating blood sampling. The urgent processing of bloods in anaemic patients enables us to diagnose iron deficiency rapidly and to deliver our intravenous iron intervention during the clinic attendance. Where the blood results demonstrate macrocytosis, B~12~ and folate concentrations can also be added to the initial blood sample during the same clinic visit.

Results {#s6}
=======

The characteristics displayed in [table 1](#T1){ref-type="table"} confirm that the audit sample selected via the database of major operations was comparable between the three time points; there are more cases at baseline, possibly due to a 7-month sample or natural variation. The age, gender and types of surgery are comparable.

Incidence of preoperative anaemia {#s6-1}
---------------------------------

The baseline audit reported a wide range of preoperative Hb concentrations: median 125.5 (range 77--171) g/L for this population in 2013--2014. An increase in median preoperative Hb and a reduction in the range of values is seen after QI cycle 1 in 2017 (131 (range 98--159) g/L) and sustained into 2018 after QI cycles 2 and 3 (130 (range 95--174) g/L) (see [table 1](#T1){ref-type="table"}). There is a narrowing of the range of preoperative Hb after the intervention.

Severe preoperative anaemia (Hb\<100 g/L) was recorded for 10% of patients in 2014. This has been reduced to 1.6% in 2017; the change is sustained into 2018 (see [figure 3](#F3){ref-type="fig"}).

![Preoperative Hb concentration measured at baseline (2013--2014, shown in red), after cycle 1 (2017, shown in dark blue) and after cycle 3 (2018, in light blue). Hb, haemoglobin.](bmjoq-2019-000776f03){#F3}

The incidence of anaemia as defined by the Munoz et al consensus statement (Hb\<130 g/L) was 58% in 2014, falling to 44% in 2017 and 44% in 2018.

Identifying anaemic patients and interventions in PAC {#s6-2}
-----------------------------------------------------

The number of patients presenting to the PAC with anaemia is comparable between 2017 and 2018. No data are available for 2014 as this did not form part of the baseline audit; rather, the intervention was instigated based on these data. However, in 2018, the proportion of patients with iron deficiency anaemia at presentation was higher than that in 2017 (24.6% vs 14.5%, respectively).

In 2018, 20/61 patients received intravenous iron. This was given to 15 patients with iron deficiency anaemia defined within the guideline as Hb\<130 g/L and ferritin\<30 μg/L, as seen in [table 2](#T2){ref-type="table"}. Six further infusions were prescribed to patients where ferritin\>30 μg/L and other iron studies confirmed iron deficiency, or to patients with non-anaemic iron deficiency (Hb\>130 g/L, ferritin\<30 μg/L) (see [table 2](#T2){ref-type="table"}).

###### 

Analysis of presenting blood investigations done within anaemia pathways in preassessment clinic within PDSA cycle 1 (2017) and cycle 3 (2018)

                                                                                2017 (n=62)                2018 (n=61)
  ----------------------------------------------------------------------------- -------------------------- --------------------------
  Hb measured at PAC (g/L)                                                      135 (122--146) (88--159)   132 (117--144) (77--179)
  MCV (fL)                                                                      90 (88--94) (70--105)      88 (85--93) (66--109)
  Ferritin concentration (μg/L)                                                 91 (31--177) (14--514)     55 (29--161) (4--743)
  Patients with Hb\<130 g/L and ferritin\<30 μg/L (iron deficiency anaemia)     9 (14.5%)                  15 (24.6%)
  Number of patients with Hb\>130 g/L and ferritin\<30 μg/L (iron deficiency)   4 (6.4%)                   6 (9.8%)
  Interventions                                                                                            
   Intravenous iron\*                                                           14/62                      20/61
   Oral iron                                                                    Unknown                    2/61
   B~12~/folate                                                                 Unknown                    1/61
   No intervention                                                              48/62                      32/61
  Unknown                                                                                                  6/61
   Intravenous iron dose (mg)\*                                                 1000 (500--1000)           1400 (1000--2000)
   Time between intravenous iron and surgery (days)                             Unknown                    116 (31--136) (20--194)
   Adverse events related to intravenous iron infusion                          0                          0

Values are median (IQR) (range) or number (proportion).

\*In 2017, this was 1 g ferric carboxymaltose; in 2018, this was 20 mg/kg iron isomaltoside.

Hb, haemoglobin; MCV, Mean corpuscular volume; PAC, preoperative assessment clinic; PDSA, plan--do--study--act.

The change in Hb due to the iron infusion is difficult to describe within this complicated treatment pathway. There is a small group of patients who received intravenous iron within 4 weeks of surgery; in this group (median time between infusion and surgery of 23 days), the Hb increased by a median of 10 g/L (range 2--19 g/L). The majority of patients had a longer time period between intravenous iron and surgery (median 124 days, due to neoadjuvant chemotherapy). In this group, the median increase in Hb was 11 g/L, though the range was −21 to +55 g/L. (All the possible clinical events that could occur within this time frame are not documented or described.)

Blood transfusions (within 30 days of surgery) {#s6-3}
----------------------------------------------

The proportion of patients undergoing postoperative blood transfusion has declined from 16% at baseline (2014) to 6.5% in 2018 ([figure 4](#F4){ref-type="fig"}). Similarly, the number of units of red cells used by this population has declined from 33 units to 18 and 12 units in 2017 and 2018 respectively: this is a reduction of 63%. Analysis of timing of the transfusion confirms that while intraoperative transfusion remains infrequent and unpredictable, the use of blood in the period of 8--21 days postsurgery has significantly reduced. Patients who remain in the hospital (and receive blood) beyond this time have significantly prolonged stays (median length of stay after oesophagectomy is 12 days) and had significant complex postoperative complications.

![Reduction in blood usage demonstrated during the QI project between baseline usage (2013--2014) and cycle 1 (2017) and cycle 3 (2018). The number of units transfused is represented by a dashed red line. The proportion of patients receiving blood is recorded in blue bars.](bmjoq-2019-000776f04){#F4}

On inspection of the individual patients who underwent blood transfusions, we can demonstrate that the blood transfusions in 2014 were principally given to patients with anaemia. Indeed, in 2014, 12/14 patients who underwent blood transfusions were anaemic preoperatively by consensus definition: 5 of these patients had a preoperative Hb of \<95 g/L. In 2017, three patients requiring blood transfusion had preoperative anaemia (Hb 127, 114, 98 g/L), and in 2018, only one patient had preoperative anaemia (Hb 95 g/L).

Lessons and limitations {#s7}
=======================

This QI project has demonstrated the ability of a simple preoperative anaemia pathway to address the aims of treating iron deficiency anaemia before major surgery and reducing the use of blood transfusions postoperatively. We have presented our real-world experience and acknowledge that there are limitations to the outcomes and data available.

The patients managed with this pathway presented with a high incidence of anaemia similar to that previously reported for groups of patients with cancer and surgical patients presenting for major non cardiac surgery.[@R2] Gastrointestinal patients have a combination of pathophysiological mechanisms that lead to this high incidence of iron deficiency anaemia and complicate their management: they can present with chronic and/or acute blood loss, poor intake of iron (dysphagia), inflammatory hepcidin-mediated inhibition of intestinal absorption and inhibition of absorption by gastric antacids and proton pump inhibitors.[@R19] Each of these factors will have been present within our populations and will have contributed to iron deficiency and progressive anaemia.

The use of intravenous iron as part of a PBM programme is recommended by perioperative and oncological consensus guidelines to treat iron deficiency and functional anaemia (due to cancer and inflammation).[@R15] In our clinic, this therapy has reduced the proportion of patients presenting to theatre with a severe anaemia (HB\<100 g/L) from 10% to 1.6%. During the time period covered by this QI project, there were no other PBM changes instituted for this group of patients: surgical approach and intraoperative blood loss remained consistent, and oncological treatment was unchanged. We believe that the reduction in blood transfusion and prevention of severe preoperative anaemia can be attributed to the preoperative anaemia pathway.

The data presented from 2018 show that improvements from treating iron deficiency anaemia have been sustained; moreover, our pathway was incorporated into clinical care without additional resource or inconvenience to patient pathways. We have introduced our anaemia pathway to the early stages of our patient pathway in order to afford the greatest duration of time for haematopoesis; as a consequence, we have also treated patients who do not ultimately present to the operating theatre. These patients will still benefit from treatment of iron deficiency anaemia.[@R18] The introduction of POC Hb testing has facilitated diagnosis and treatment of iron deficiency anaemia during a single preassessment clinic attendance. This has streamlined the patient pathway, requiring fewer hospital attendances.

The number of units of blood transfused postoperatively has reduced by 64% since this QI project was commenced. Preoperative anaemia is associated with transfusion[@R11]; avoiding blood transfusion is desirable to reduce morbidity and the potentially harmful risks of transfusion.[@R7] We accept that we cannot prevent all transfusions with a preoperative intervention: there will undoubtedly remain patients who require blood during complex surgery or prolonged critical care stay.

Our anaemia pathways are also used for other patient groups presenting to the preoperative assessment service. We use the perioperative guideline for all patients in the clinic who meet inclusion criteria to enter the anaemia pathway, that is, operations that are commonly associated with the potential for \>500 mL blood loss. The QI project has thus improved care for a wider patient population in our clinic. Naturally, there are also other less tangible benefits that have arisen from this initiative. Awareness of iron deficiency anaemia and the ability and importance of optimising this preoperatively has increased both within and beyond the PAC during the time that this project has been running. It is difficult to quantify the benefits that word of mouth and the presence of our guideline have had on improving standards of practice.

There are limitations to the interpretation of the data presented. This is a 'real-life experience' of a clinical pathway and not a research study. We were unable to describe compliance with the pathway in 2017. Similarly, we do not have Hb measurements taken at standardised time points after intravenous iron infusion, making comparison of response difficult. There will have been many variations in care and in the events experienced by these patients. Our heterogeneous clinical population has multiple pathophysiologies driving their anaemia, as mentioned previously. The improvements described here have been effected *despite* the heterogeneous population.

Lastly, we cannot expect to eliminate preoperative anaemia completely in patients presenting for surgery for all of the reasons described. A QI intervention that is applied during preoperative work-up will not influence intraoperative blood loss or the occasional significant postoperative bleed or prevent the transfusions given to a patient who develops multiple postoperative problems culminating in multiorgan failure on critical care. These transfusions must be accepted. Similarly, there are patients within our heterogeneous population who are anaemic but do not have iron deficiency. Our pathway promotes individualised management plans for these patients directed by the PAC consultant, but some of these anaemias will not be correctable due to the causative pathology. However, the evidence presented here demonstrates that if applied preoperatively, this intervention to identify and treat iron deficiency anaemia can significantly improve preoperative Hb and reduce the overall transfusion rate.

Our QI project has evolved over time in response to our observations. Analysis of discharge Hb in our latest data capture has revealed that despite a proactive preoperative anaemia pathway, our patients are discharged from the hospital anaemic (median Hb 105 g/L). We can confirm this finding in the previous cohorts by retrospectively adding discharge Hb concentrations for the 2014 and 2017 cohorts. The NICE quality statement promotes postoperative management of iron deficiency anaemia, and a recent publication confirms the high rates of rehospitalisation and 6-month mortality rate in patients discharged from the hospital with moderate anaemia.[@R7] Consensus guidance is available to direct our fourth cycle of QI.[@R24]

Conclusion {#s8}
==========

Our QI approach to treat preoperative iron deficiency anaemia has been successful in a heterogeneous 'real-world' clinical situation. This sustainable change could be replicated in other preoperative assessment services and to this end we feel that this work should be made available for others to learn from. The work has been disseminated and presented locally; and won local QI prizes.

To sustain this improvement we must continue to promote the use of our clinical guideline both in our PAC and more widely for surgical patients throughout the hospital where it is applicable. We will continue to audit our results. Currently we record all patients who have been referred for intravenous iron through our pathway: we have introduced it to other surgical patient groups managed in the PAC. In 2018, a broad mix of patients were managed and audit data showed that the indications for treatment were met and infusions were administered appropriately. Continuing to complete this feedback loop will sustain our intervention and direct its ongoing development.

There is a lot of interest currently in this area of work, and the quality statement issued by NICE has driven hospitals to develop this area of practice. Our service has demonstrated improvement, and we consider it to have been a valuable and successful project.
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